ArticleJournal of virology2026
The FACT complex associates with the RPA complex at viral replication compartments to promote adenovirus infection.
Article in Journal of virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We have determined that the FACT (Facilitates Chromatin Transcription) complex components, SPT16 and SSRP1, associate with both the RPA (Replication Protein A) complex and adenovirus DNA-binding protein (DBP) within viral replication compartments (VRCs) during both human adenovirus 5 (Ad5) and adenovirus 12 (Ad12) infection, and possess proviral activities. Inactivation of FACT by the curaxin, CBL0137, reduces Ad5 and Ad12 E1A-dependent induction of early gene products, while inhibition of FACT by siRNA similarly affected Ad5 gene product synthesis, but differentially affected Ad12 gene product expression. A consistent feature of FACT inhibition, however, was a significant reduction in the protein levels of DBP, which correlated positively with a significant reduction in the formation of VRCs during infection, and the production of new, infectious virus. Pertinently, the inactivation of FACT with CBL0137 or siRNA increased the levels of the p53 protein and p53 target gene product, p21
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.